Stocklytics Platform
Asset logo for symbol RARE
Ultragenyx Pharmaceutical
RARE60
$44.85arrow_drop_down0.46%-$0.21
Asset logo for symbol RARE
RARE60

$44.85

arrow_drop_down0.46%

Performance History

Chart placeholder
Key Stats
Open$45.56
Prev. Close$45.06
EPS-7.95
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range44.41
45.90
52 Week Range31.52
54.56
Ratios
EPS-7.95

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$804.62
Perf. (24h)
arrow_drop_down2.01%-$16.57
Market Cap$724.48B
Price$569.71
Perf. (24h)
arrow_drop_up1.79%$10.03
Market Cap$527.83B
Price$160.64
Perf. (24h)
arrow_drop_up0.62%$1.00
Market Cap$386.60B
Price$185.16
Perf. (24h)
arrow_drop_up1.64%$2.99
Market Cap$326.96B

About Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc (RARE) is a biopharmaceutical company focused on the development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases. The company's mission is to bring transformative therapies to patients with limited or no treatment options. With a market capitalization of over $10 billion, Ultragenyx is one of the leading companies in the rare disease space.
Ultragenyx's stock price history reflects the company's growth and development over the years. Starting from its initial public offering (IPO) in 2014, the stock has experienced both ups and downs, as is common in the biotech industry. However, it has demonstrated resilience and shown significant growth potential. The company has been able to attract investors with its innovative pipeline and promising drug candidates.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Emil D. Kakkis M.D., Ph.D.
Headquarters
Novato
Employees
1311
Exchange
NASDAQ
add Ultragenyx Pharmaceutical  to watchlist

Keep an eye on Ultragenyx Pharmaceutical

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Ultragenyx Pharmaceutical 's (RARE) price per share?
The current price per share for Ultragenyx Pharmaceutical (RARE) is $44.85. The stock has seen a price change of -$0.21 recently, indicating a -0.47% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Ultragenyx Pharmaceutical (RARE)?
For Ultragenyx Pharmaceutical (RARE), the 52-week high is $54.56, which is 21.65% from the current price. The 52-week low is $31.52, the current price is 42.29% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Ultragenyx Pharmaceutical (RARE) a growth stock?
Ultragenyx Pharmaceutical (RARE) has shown an average price growth of 0.41% over the past three years. It has received a score of 23 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Ultragenyx Pharmaceutical as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Ultragenyx Pharmaceutical (RARE) stock price performance year to date (YTD)?
As of the latest data, Ultragenyx Pharmaceutical (RARE) has a year-to-date price change of -6.89%. Over the past month, the stock has experienced a price change of 10.66%. Over the last three months, the change has been 1.38%. Over the past six months, the figure is -0.27%. Looking at a longer horizon, the five-year price change stands at -27.95%.
help
Is Ultragenyx Pharmaceutical (RARE) a profitable company?
Ultragenyx Pharmaceutical (RARE) has a net income of -$606.64M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 89.59% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -151.93% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $434.25M, with a revenue growth rate of 19.52%, providing insight into the company's sales performance and growth. The gross profit is $389.04M. Operating income is noted at -$569.21M. Furthermore, the EBITDA is -$550.84M.
help
What is the market capitalization of Ultragenyx Pharmaceutical (RARE)?
Ultragenyx Pharmaceutical (RARE) has a market capitalization of $4.09B. The average daily trading volume is 625.52K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level